Let’s Talk Medtech

Holley Miller, founder and President of Grey Matter Marketing, is our guest on this episode of Let's Talk Medtech to discuss why it's so crucial to have the right message for your product.

Join Marissa Fayer, CEO of HerHealthEQ and DeepLook Medical, as she explores the future of women's health and what it could look like in 2026 in this insightful episode of Let's Talk Medtech.

Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, enabling the optimization and personalization of treatment options for patients. Neil Klompas, the firm’s CEO, joins us for this episode of Let’s Talk Medtech to discuss how the company aims to accelerate the diagnosis of the disease and enhance autoimmune diagnostics for patients.

Surgical robotics is changing the landscape in healthcare. Stereotaxis is hoping to carve out its niche in the massive space, which is home to Intuitive Surgical, Johnson & Johnson, and Medtronic.David Fischel, the St. Louis, MO-based company’s chairman and CEO, is featured in this episode of Let’s Talk Medtech to discuss Stereotaxis’ journey from surviving to thriving. The firm recently secured $50 million in funding and has had strong collaborations with NVIDIA.Fischel talks about the company’s game plan and his thoughts on the future of surgical robotics.

Audacity is defined as the willingness to take bold risks. It’s also a mantra for Lishan Aklog, MD, a co-founder and CEO PavMed, the parent company of Lucid Diagnostics. Aklog makes his second appearance on Let’s Talk Medtech to give updates on both companies and to discuss his philosophy on why audacity breeds innovation.

Join us for an insightful episode of Let's Talk Medtech, featuring EY's experts John Babitt and Arda Ural. Our guests delve into EY's latest Pulse of the Medtech Industry Report. They take a deep dive into the state of the medtech industry, examining whether the sector is thriving and assessing the real-world impact of tariffs on medical device companies.Discover which medtech segment is experiencing explosive growth right now and learn why mid-tier companies are gaining unprecedented momentum in the marketplace. From industry health assessments to emerging market trends, this episode delivers essential insights for anyone invested in the future of medical technology.Don't miss this comprehensive discussion that addresses the most pressing questions shaping today's medtech landscape.

Welcome back to Let's Talk Medtech, where we're joined by returning guest Paul Grand, CEO of MedTech Innovator, for an essential conversation on securing capital in the medical technology space.In this value-packed episode, Paul reveals why successful fundraising requires a comprehensive, holistic approach rather than a narrow focus. He maps out proven strategies for medtech startups to attract and secure investment at various stages of development, drawing from his extensive experience in the industry.Paul also shares remarkable insights into how MedTech Innovator has successfully connected over 700 promising companies with investors, helping transform innovative ideas into market-ready healthcare solutions.Whether you're a medtech entrepreneur seeking funding, an investor looking for opportunities, or simply interested in the business of medical innovation, this episode delivers actionable wisdom from one of the industry's most respected voices.Subscribe to Let's Talk Medtech for more expert conversations on navigating the complex world of medical technology development and commercialization.

In this episode of Let's Talk Medtech, AngioDynamics CEO James Clemmer shares insights into what has been a transformative year for the medical device company across multiple therapeutic areas.Clemmer highlighted several significant achievements that have strengthened the company's position in both oncology and vascular care. He also describes how a crucial pivot helped redefine AngioDynamics.

MD+DI Senior Editor Amanda Pedersen breaks down the most significant mid-year trends shaping the medical device industry in this insightful episode of Let's Talk Medtech. Get her expert analysis on market developments, regulatory changes, and emerging technologies that are transforming healthcare innovation.Whether you're a medical device professional, healthcare provider, or industry investor, this episode delivers valuable insights to help you navigate the evolving medtech landscape. Subscribe for regular updates on industry news, expert interviews, and in-depth analysis of the technologies revolutionizing patient care.

In a significant industry move this February, Baxter completed the sale of its kidney care business to The Carlyle Group, creating Vantive—a company now experiencing a unique balance of established expertise and newfound agility.CEO Chris Toth recently shared Vantive's ambitious vision, highlighting the firm's commitment to investing over $1 billion in digitally-enabled kidney care solutions. Toth discussed how this strategic separation has empowered the company to maintain its valuable legacy while gaining the flexibility to execute decisions more rapidly.During the conversation, Toth also offered personal insights into his role as a medtech CEO and shared his deep passion for Vantive's mission to transform kidney care.